Molecular Diagnostics for Precision Medicine
Lawrence Berkeley National Laboratory
Predicting a cancer patient’s response to radiation or chemotherapy
informs treatment choices that improve quality of life and enable
efficient allocation of medical and financial resources.
Following
are
representative
Berkeley
Lab
technologies
in
this
portfolio:
12-‐Gene
Prognostic
Signature
for
Breast
Cancer
Survival
(2016-‐181)
Breast
cancer
oncologists
lack
prognostic
markers
that
indicate
which
patients
will
benefit
from
adjuvant
therapy
and
which
patients
should
be
spared
its
toxic
effects.
This
12-‐gene
signature
provides
a
way
to
predict
patient
prognosis
without
regard
to
conventional
factors
such
as
tumor
size,
histological
grade,
lymph
node
involvement,
etc.
The
signature
has
been
validated
using
a
multigene
co-‐expression
network
analysis.
Gene
Signatures
that
Predict
Survival
Benefit
from
Radiotherapy
in
Luminal
A
and
Basal
Type
Breast
Cancer
Patients
(2017-‐037)
The
relative
levels
of
seven
(7)
genes
for
Luminal
Type
A
breast
cancer
and
a
unique
set
of
17
genes
for
Basal
Type
breast
cancer
predict
survival
after
radiation
therapy
for
each
subtype.
The
gene
signatures
could
function
as
a
prognostic
test
applied
to
resected
tumor
tissue
and
could
enable
a
more
effective
assignment
of
patients
to
alternative
cancer
therapies,
minimizing
unnecessary
toxic
therapy
and
preserving
physical
resources
for
recovery.
Centromere
/
Kinetochore
Protein
Genes
for
Cancer
Prognosis,
Diagnosis,
and
Treatment
(2013-‐163)
Unlike
cancer
diagnostics
and
therapies
that
measure
tumor
cell
growth,
this
Berkeley
Lab
technology
targets
the
centromere
and
kinetochore
pathway.
The
altered
expression
of
a
signature
of
21
Centromere
/
Kinetochore
(CEN/KT)
genes
and
proteins
is
linked
to
the
progression
of
breast,
stomach,
brain,
prostate,
lung
and
other
cancers
to
specific
clinical
stages
such
as
metastasis.
This
technology
has
the
potential
to
identify
patients
at
high
risk
for
aggressive
cancer
at
early
disease
stages,
predict
survival
rates
and
metastatic
relapse
for
patients
being
treated
for
cancer,
and
reduce
radiation
therapy
overtreatment
of
cancer
patients.
It
also
supports
the
development
of
new
targets
for
cancer
therapy.
27-‐Gene
Prognostic
Signature
for
Lung
Cancer
Survival
(2017-‐082)
Details
will
be
released
this
summer.
For
information
on
partnership
opportunities:
Peter
Bluford,
Technology
Commercialization
Associate
[email protected],
510-‐486-‐7954
ipo.lbl.gov